Beibei Guo

Beibei Guo


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 July 2025 in Materials Today Bio
Verified
Journal Article
Open access
SWSizhen Wang
Sizhen Wang
JZJianyu Zheng
Jianyu Zheng
JZJiao Zhou
Jiao Zhou
WJWeiwei Jiang
Weiwei Jiang
ZCZhendong Chen
Zhendong Chen
FYFeng Yang
Feng Yang
Lipid nanoparticles (LNPs) have emerged as a pivotal carriers for enhancing mRNA therapeutics, particularly in antitumor therapy. However, achieving robust antigen expression remains a major challenge due to limitations in precise targeted delivery and inefficient endosomal escape. In this study, we constructed an ambidextrous LNP to achieve robust tumor-specific antigen expression through targeted cell delivery and enhanced endosomal escape of mRNA-LNPs. To improve endosomal escape, we synthesized a novel pH-responsive PEGylated lipid designed to synergistically enhance membrane fusion effect with ionizable lipids, thereby optimizing the translation of the desired antigen. This is accomplished by promoting the early endosomal escape and endosomal recycling transport. For precise delivery of mRNA-LNPs to dendritic cells, we employed a mannose-modified PEGylated lipid that targets mannose receptors. Our results demonstrated that the combination of mannose-directed targeting and pH-mediated endosomal escape significantly enhances antigen translation and expression, leading to a vigorous immune response, as validated by both in vitro and in vivo experiments. This ambidextrous strategy advances the formulation of LNPs for precise mRNA delivery and effective antigen encoding, facilitating the development of mRNA vaccines in the field of antitumor immunology.

14 February 2026 in Drug Delivery
Verified
Journal Article
Open access
GSGuangze Sang
Guangze Sang
SWSizhen Wang
Sizhen Wang
QTQiwei Tai
Qiwei Tai
YZYunchang Zhang
Yunchang Zhang
XWXufang Wang
Xufang Wang
BGBeibei Guo
Beibei Guo
Inflammatory bowel disease (IBD), an immune-mediated chronic gastrointestinal disease, is difficult to treat because its specific pathogenic mechanisms are currently unclear, and its recurrence rate is high. Probiotic therapies have been used to treat IBD; however, challenges, including poor digestive stability and unstable treatment effects, remain. Catechins are natural flavonoids with anti-inflammatory and anti-oxidant properties. In this study, we link catechins to the amino side chain of ethylene glycol chitosan through phenylboronic acid as a nano coating for probiotics, and enhance their stability under acidic conditions with sodium alginate. The resulting double-layer nano coating system is triggered by reactive oxygen species (ROS) for probiotic-small molecule combination therapy. After oral administration, the nano coating helps probiotics stabilize and pass through the harsh digestive environment, respond to the high ROS environment at the site of inflammation, and release anti-inflammatory drugs. The coating breaks down and adheres to the cell surface while releasing probiotics to regulate the intestinal microbiota environment and achieve combined therapy. The method exerts a certain therapeutic effect in a dextran sulfate sodium (DSS)-induced mouse model of ulcerative colitis. This study combines traditional targeted drug therapy concepts with biological therapies to improve IBD treatment efficacy and reduce side effects.

10 June 2026 in Journal of Nanobiotechnology
Verified
Journal Article
Open access
ZCZhendong Chen
Zhendong Chen
JZJiao Zhou
Jiao Zhou
SWSizhen Wang
Sizhen Wang
TCTianheng Chen
Tianheng Chen
FAFrancisco Aznarez
Francisco Aznarez
BGBeibei Guo
Beibei Guo
Metal-coordinated hydrogels offer a strategy to integrate local drug retention, responsive release, and multimodal therapy, but assigning structural and therapeutic roles to a single metal complex remains challenging. Here, we report an injectable polypyridyl Ru(II)-scaffolded hydrogel, Ru(fmb)3HADH-PDA@IR780, formed by dynamic Schiff-base crosslinking and loaded with polydopamine nanoparticles carrying IR780. In this platform, PDA@IR780 enables 808 nm near-infrared-activated photothermal and photodynamic outputs whereas the Ru(II) complex functions as both a hydrogel crosslinking unit and a redox-active therapeutic component. This formulation demonstrates dual pH/photo-responsiveness: acidic tumor microenvironment (TME) promoted formulation release, and NIR irradiation triggered rapid local heating and reactive oxygen species (ROS) generation. In vitro, the hydrogel produced enhanced tumor-cell killing through combined photothermal, photodynamic, and Ru-associated oxidative and chemodynamic therapy (CDT), accompanied by glutathione depletion and lipid-peroxidation-related stress. In vivo, local administration followed by short NIR irradiation markedly suppressed tumor growth, increased tumor-cell apoptosis, prolonged tumor-site retention, and showed no obvious short-term systemic toxicity under the tested regimen. Transcriptomic and histological analyses further suggested treatment-associated redox disruption and favorable modulation of the local immune microenvironment. This Ru(II)-scaffolded hydrogel provides a component-defined, single-wavelength-activated platform for locally retained multimodal tumor therapy. Notably, this work represents the first report of a polypyridyl Ru(II)-scaffolded hydrogel that unifies Ru(II)'s structural coordination with intrinsic therapeutic action, offering a translational strategy for synergistic, site-selective tumor therapy.

21 June 2026 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SWSizhen Wang
Sizhen Wang
QTQiwei Tai
Qiwei Tai
KWKehui Wang
Kehui Wang
JZJianyu Zheng
Jianyu Zheng
BGBeibei Guo
Beibei Guo
CWChen Wang
Chen Wang
Background/Objectives: Lipid nanoparticles (LNPs) have emerged as crucial vehicles for messenger RNA (mRNA) applications in antitumor therapy. Combining LNPs with stimulator of interferon genes (STING) activation holds promise for treating “cold” tumors such as pancreatic cancer. However, two major challenges remain: inefficient mRNA escape from endosomes and STING pathway suppression in immunosuppressive tumor microenvironments. Methods: To improve endosomal escape, we developed a novel pH-responsive PEGylated lipid (Ben-mPEG2000) for mRNA-LNP preparation while using commercial Man-mPEG2000 for dendritic cell (DC)-targeted delivery of LNPs; to alleviate suppression of the STING pathway in the tumor microenvironment and activate immune responses, STING-R283S mRNA was encapsulated into LNPs, ultimately resulting in DC-targeted/pH-responsive LNPs loaded with STING-R283S mRNA for pancreatic cancer immunotherapy research. Results: After pH-responsive cleavage, Ben-mPEG2000 not only enhanced the positive charge of LNPs through the exposed protonated amino groups but also eliminated the PEG-induced steric hindrance effect. The combination of these two effects promoted membrane fusion between LNPs and the endosome, thereby enhancing mRNA translation. As a payload, STING-R283S could further amplify STING signaling in DCs without cytotoxicity to counteract immunosuppression in pancreatic cancer. Conclusions: This engineered LNP platform enhanced mRNA expression and STING activation in DCs, improving immunotherapy outcomes in pancreatic cancer.